Skip to main content

Advertisement

SpringerLink
Log in

Increasing levels of serum antioxidant status, total antioxidant power, in systemic sclerosis

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Oxidative stress is one of the important factors that contribute to tissue damage in systemic sclerosis (SSc). Since the physiological response to oxidative stress is regulated by multiple antioxidant systems, it is important to measure quantitatively the total antioxidant capacity in the biological specimens. To determine the clinical significance of total antioxidant power (TAP) in SSc, we investigated the prevalence and clinical correlation of serum TAP levels in SSc patients. Serum TAP levels were examined in 49 patients with SSc by colorimetric microplate assay. The assay measures the total abilities for reducing Cu++ into Cu+. Clinical evaluation including medical history, physical examination, and laboratory tests were conducted for all SSc patients. Serum TAP levels were significantly elevated in SSc patients compared to normal controls (p < 0.01). When values higher than the mean + 2SD of the control serum samples were considered to be elevated, TAP levels were elevated in 24% of total SSc patients, with 26% of diffuse cutaneous SSc patients and 23% of limited cutaneous SSc patients. Serum TAP levels were correlated positively with C-reacting protein (r = 0.35, p ≤ 0.05). However, no other significant correlation was observed between serum TAP levels and clinical features in SSc patients. These results suggested that oxidative stress is enhanced in SSc patients, and serum TAP levels increase as an indicator of the global response to oxidative stress.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Herrick AL, Rieley F, Schofield D, Hollis S, Braganza JM, Jayson MI (1994) Micronutrient antioxidant status in patients with primary Raynaud’s phenomenon and systemic sclerosis. J Rheumatol 21:1477–1483

    PubMed  CAS  Google Scholar 

  2. Sambo P, Baroni SS, Luchetti M, Paroncini P, Dusi S, Orlandini G et al (2001) Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum 44:2653–2664

    Article  PubMed  CAS  Google Scholar 

  3. Butler AR, Flitney FW, Williams DL (1995) NO, nitrosonium ions, nitroxide ions, nitrosothiols and iron-nitrosyls in biology: a chemist’s perspective. Trends Pharmacol Sci 16:18–22

    Article  PubMed  CAS  Google Scholar 

  4. Suematsu M, Wakabayashi Y, Ishimura Y (1996) Gaseous monoxides: a new class of microvascular regulator in the liver. Cardiovasc Res 32:679–686

    PubMed  CAS  Google Scholar 

  5. Andersen GN, Caidahl K, Kazzam E, Petersson AS, Waldenstrom A, Mincheva-Nilsson L et al (2000) Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis: findings with the soluble adhesion molecules E-selectin, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1. Arthritis Rheum 43:1085–1093

    Article  PubMed  CAS  Google Scholar 

  6. Ogawa F, Shimizu K, Muroi E, Hara T, Hasegawa M, Takehara K et al (2006) Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with systemic sclerosis. Rheumatology (Oxford) 45:815–818

    Article  CAS  Google Scholar 

  7. Ogawa F, Shimizu K, Hara T, Muroi E, Hasegawa M, Takehara K et al (2008) Serum levels of heat shock protein 70, a biomarker of cellular stress, are elevated in patients with systemic sclerosis: association with fibrosis and vascular damage. Clin Exp Rheumatol 26:659–662

    PubMed  CAS  Google Scholar 

  8. Thiele JJ, Schroeter C, Hsieh SN, Podda M, Packer L (2001) The antioxidant network of the stratum corneum. Curr Probl Dermatol 29:26–42

    Article  PubMed  CAS  Google Scholar 

  9. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J (2007) Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39:44–84

    Article  PubMed  CAS  Google Scholar 

  10. Ogawa F, Sander CS, Hansel A, Oehrl W, Kasperczyk H, Elsner P et al (2006) The repair enzyme peptide methionine-S-sulfoxide reductase is expressed in human epidermis and upregulated by UVA radiation. J Invest Dermatol 126:1128–1134

    Article  PubMed  CAS  Google Scholar 

  11. Simonini G, Cerinic MM, Generini S, Zoppi M, Anichini M, Cesaretti C et al (1999) Oxidative stress in systemic sclerosis. Mol Cell Biochem 196:85–91

    Article  PubMed  CAS  Google Scholar 

  12. (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 23: 581–590.

  13. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–205

    PubMed  CAS  Google Scholar 

  14. Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P et al (1993) Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 20:1892–1896

    PubMed  CAS  Google Scholar 

  15. Sato S, Ihn H, Kikuchi K, Takehara K (1994) Antihistone antibodies in systemic sclerosis. Association with pulmonary fibrosis. Arthritis Rheum 37:391–394

    Article  PubMed  CAS  Google Scholar 

  16. Nishijima C, Sato S, Hasegawa M, Nagaoka T, Hirata A, Komatsu K et al (2001) Renal vascular damage in Japanese patients with systemic sclerosis. Rheumatology (Oxford) 40:406–409

    Article  CAS  Google Scholar 

  17. Simonini G, Pignone A, Generini S, Falcini F, Cerinic MM, Gabriele S et al (2000) Emerging potentials for an antioxidant therapy as a new approach to the treatment of systemic sclerosis. Toxicology 155:1–15

    Article  PubMed  CAS  Google Scholar 

  18. Peng SL, Fatenejad S, Craft J (1997) Scleroderma: a disease related to damaged proteins? Nat Med 3:276–278

    Article  PubMed  CAS  Google Scholar 

  19. Iwata Y, Ogawa F, Komura K, Muroi E, Hara T, Shimizu K et al (2007) Autoantibody against peroxiredoxin I, an antioxidant enzyme, in patients with systemic sclerosis: possible association with oxidative stress. Rheumatology (Oxford) 46(5):790–795

    Article  CAS  Google Scholar 

  20. Servettaz A, Goulvestre C, Kavian N, Nicco C, Guilpain P, Chereau C et al (2009) Selective oxidation of DNA topoisomerase 1 induces systemic sclerosis in the mouse. J Immunol 182:5855–5864

    Article  PubMed  CAS  Google Scholar 

  21. Lundberg AC, Akesson A, Akesson B (1992) Dietary intake and nutritional status in patients with systemic sclerosis. Ann Rheum Dis 51:1143–1148

    Article  PubMed  CAS  Google Scholar 

  22. Simonini G, Pignone A, Generini S, Falcini F, Cerinic MM (2000) Emerging potentials for an antioxidant therapy as a new approach to the treatment of systemic sclerosis. Toxicology 155:1–15

    Article  PubMed  CAS  Google Scholar 

  23. Tikly M, Channa K, Theodorou P, Gulumian M (2006) Lipid peroxidation and trace elements in systemic sclerosis. Clin Rheumatol 25:320–324

    Article  PubMed  Google Scholar 

  24. Morita A, Minami H, Sakakibara N, Sato K, Tsuji T (1996) Elevated plasma superoxide dismutase activity in patients with systemic sclerosis. J Dermatol Sci 11:196–201

    Article  PubMed  CAS  Google Scholar 

  25. Firuzi O, Fuksa L, Spadaro C, Bousova I, Riccieri V, Spadaro A et al (2006) Oxidative stress parameters in different systemic rheumatic diseases. J Pharm Pharmacol 58:951–957

    Article  PubMed  CAS  Google Scholar 

  26. Sfrent-Cornateanu R, Mihai C, Stoian I, Lixandru D, Bara C, Moldoveanu E (2008) Antioxidant defense capacity in scleroderma patients. Clin Chem Lab Med 46:836–841

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We thank Ms. A. Usui, M. Yozaki, and K. Shimoda for technical assistance.

This work was supported by a grant of Research on Intractable Diseases from the Ministry of Health, Labour and Welfare of Japan.

Disclosures

None.

Author information

Authors and Affiliations

  1. Department of Dermatology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan

    Fumihide Ogawa, Kazuhiro Shimizu, Eiji Muroi & Toshihide Hara

  2. Department of Dermatology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan

    Shinichi Sato

Authors
  1. Fumihide Ogawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazuhiro Shimizu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eiji Muroi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Toshihide Hara
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shinichi Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shinichi Sato.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ogawa, F., Shimizu, K., Muroi, E. et al. Increasing levels of serum antioxidant status, total antioxidant power, in systemic sclerosis. Clin Rheumatol 30, 921–925 (2011). https://doi.org/10.1007/s10067-011-1695-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-011-1695-4

Keywords

Search

Navigation